Invasive papillary carcinomas of the extrahepatic bile ducts: A clinicopathologic and immunohistochemical study of 13 cases

Modern Pathology

Volumn 15, Issue 12, 2002, Pages 1251-1258

  Hoang, Mai P ^a   Murakata, Linda A ^c   Katabi, Nora ^b   Henson, Donald E ^d   Albores Saavedra, Jorge ^a,e  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Extrahepatic bile ducts; Immunohistochemistry; Papillary carcinoma

Indexed keywords

KI 67 ANTIGEN; PROTEIN P53; SMAD4 PROTEIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CANCER INVASION; CHOLEDOCHOTOMY; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; EPIDEMIOLOGICAL DATA; EXTRAHEPATIC BILE DUCT OBSTRUCTION; FEMALE; FOLLOW UP; HEALTH SURVEY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; JAUNDICE; LIVER LOBECTOMY; LYMPH NODE METASTASIS; MALE; MEDICAL RECORD; MINIMALLY INVASIVE SURGERY; NON INVASIVE MEASUREMENT; PANCREATICODUODENECTOMY; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL; TREATMENT OUTCOME; TUMOR LOCALIZATION;

ADULT; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, EXTRAHEPATIC; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, PAPILLARY; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-7; KERATINS; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; SMAD4 PROTEIN; SURVIVAL ANALYSIS; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 18744366024     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MP.0000036450.61830.8E     Document Type: Article

References (22)

1. Albores-Saavedra J, Henson DE, Klimstra D. Tumors of the gallbladder, extrahepatic bile ducts, and ampulla of Vater. 3rd Ed, Fascicle 27. Washington, DC: Armed Forces Institute of Pathology; 2000.
2. Henson DE, Albores-Saavedra J, Corle D. Carcinoma of the extrahepatic bile ducts. Histologic types, stage of disease and survival rates. Cancer 1992;70:1498-501.
3. Albores-Saavedra J, Murakata L, Krueger JE, Henson DE. Noninvasive and minimally invasive papillary carcinomas of the extrahepatic bile ducts. Cancer 2000;89:508-15.
4. Baas IO, Mulder JR, Offerhaus GJA, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994;172:5-12.
5. Rullier A, Le Bail B, Fawaz R, Blanc JF, Sahic J, Bioulac-Sage P. Cytokeratin 7 and 20 expression in cholangiocarcinomas varies from that in colorectal carcinoma metastasis. Am J Surg Pathol 2000;24:870-6.
6. Maxwell P, Davis RI, Sloan JM. Carcinoembryonic antigen (CEA) in benign and malignant epithelium of the gallbladder, extrahepatic bile ducts, and ampulla of Vater. J Pathol 1993;170:73-6.
7. Nakeeb A, Lipsett PA, Lillemoe KD, Fox-Talbot MK, Coleman J, Cameron JL, et al. Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma. Am J Surg 1996;171:147-52.
8. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991;351:453-6.
9. Hruban RH, Offerhaus GJA, Kern SE, Goggins M, Wilentz RE, Yeo CJ. Tumor-suppressor genes in pancreatic cancer. J Hepatobiliary Pancreatic Surg 1998;5:383-91.
10. Teh M, Wee A, Raju GC. An immunohistochemical study of p53 protein in gallbladder and extrahepatic bile duct/ampullary carcinomas. Cancer 1994;74:1542-5.
11. Washington K, Gotffried MR. Expression of p53 in adenocarcinoma of the gallbladder and bile ducts. Liver 1996;16:99-104.
12. Argani P, Shaukat A, Kaushal M, Wilentz RE, Su GH, Sohn TA, et al. Differing rates of loss of Dpc4 expression and of p53 overexpression among carcinomas of the proximal and distal bile ducts: Evidence for a biologic distinction. Cancer 2001;91:1332-41.
13. Diamantis I, Karamitopoulou E, Perentes E, Zimmerman A. P53 protein immunoreactivity in extrahepatic bile duct and gallbladder cancer: Correlation with tumor grade and survival. Hepatology 1995;22:774-9.
14. Suto T, Sugai T, Nakamura D-I, Funato O, Nitta H, Sasaki R, et al. Assessment of the expression of p53, MIB-1 (Ki-67 antigen), and argyrophilic nucleolar organizer regions in carcinoma of the extrahepatic bile duct. Cancer 1998;82:79-85.
15. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-5.
16. Hahn SA, Bartsch D, Schroers A, Galehdari H, Becker M, Ramaswamy A, et al. Mutations of the DPC4/Smad4 gene in biliary tract carcinoma. Cancer Res 1998;58:1124-6.
17. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, et al. DPCA, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996;271:350-3.
18. Schutte M. DPC4/SMAD4 gene alterations in human cancer and their functional implications. Annu Oncol 1999; 10(Suppl 4):56-9.
19. Schutte M, Hruban RH, Hedrick L, Cho KR, Nadasky GM, Weinstein CL, et al. DPC4 gene in various tumor types. Cancer Res 1996;56:2527-30.
20. Riggins GJ, Kinzler KW, Vogelstein B, Thiagalingam S. Frequency of Smad gene mutations in human cancers. Cancer Res 1997;57:2578-80.
21. Zhou S, Buckhaults P, Zawel L, Bunz F, Riggins G, Dai IL, et al. Targeted deletion of Smad4 shows it is required for transforming growth factor b and activin signaling in colorectal cancer cells. Proc Natl Acad Sci U S A 1998;95:2412-6.
22. Rijiken AM, Hu J, Perlman E, Morsberger LA, Long P, Kern SE, et al. Genomic alterations in distal bile duct carcinoma by comparative genomic hybridization and karyotype analysis. Genes Chromosomes Cancer 1999;26:185-91.